Results 141 to 150 of about 65,232 (224)

A Novel BRCA1 Pathogenic Variant in Tunisian Patient With High Grade Ovarian Cancer: Favorable Therapeutic Response to Olaparib

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Ovarian cancer is one of the leading causes of death from gynecological cancer worldwide. Genetic mutations in genes involved in key cellular functions such as BRCA1/2 play a central role in tumorigenesis and have major implications for targeted therapeutic strategies, especially the use of poly (ADP‐ribose) polymerase (PARP ...
Nihel Ammous‐Boukhris, Rania Abdelmaksoud‐Dammak, Ameni Feki, Souhir Khemiri, Slim Charfi, Tahia Sallemi‐Boudawara, Jamel Daoud, Afef Khanfir, Raja Mokdad Gargouri   +8 more
wiley   +1 more source

Spatiotemporal immune heterogeneity and precision immunotherapy for ovarian cancer

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
Graphical Highlights Spatiotemporal immune heterogeneity shapes distinct and evolving immune ecosystems in ovarian cancer. Multimodal biomarkers enable biologically informed patient stratification beyond static single‐marker approaches. Precision immunotherapy should match dominant immune barriers across lesions and treatment stages.
Xinfeng Yang, Yida Wang, Haiyue You, Jingyi Gao, Yangkun Feng, Feng Zhang, Yan Zhang, Bing Zhang, Shaojie Zhao, Yanfang Gu   +9 more
wiley   +1 more source

STN1 upregulation promotes PARPi resistance in BRCA2-deficient cancer cells via replication fork protection and suppression of ssDNA gap formation. [PDF]

NAR Cancer
Laghari ZA, Li N, Gayybov S, Wang QE, Chai W.   +4 more
europepmc   +1 more source

Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors: A position paper from the FIGO Committee on Women at Menopausal Age

International Journal of Gynecology &Obstetrics, Volume 174, Issue 3, Page 1151-1171, September 2026.
Abstract Recent advances in cancer screening, diagnosis, and treatment have greatly improved survival rates among women with gynecologic cancers. More survivors now live long enough to experience treatment‐related menopause. Vasomotor symptoms, genitourinary syndrome of menopause, sexual dysfunction, sleep issues, and long‐term risks from estrogen ...
Agnaldo Lopes da Silva‐Filho, Suvarna Khadilkar, Hema Divakar, Chiara Benedetto, Andrea R. Genazzani, Diana Ramos, Elizabete Argale, Enrique Herrera, Martha Hickey   +8 more
wiley   +1 more source

Real-World Outcomes of Olaparib in Japanese Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of BRCA2 Loss and Microsatellite Instability Status. [PDF]

Int J Urol
Nukaya T, Naiki T, Watanabe H, Nakane K, Inamoto T, Yasui T, Koie T, Takahara K.   +7 more
europepmc   +1 more source

Urethral Metastasis of Therapy‐Induced Neuroendocrine Prostate Cancer Successfully Managed With Chemoradiotherapy: A Case Report

IJU Case Reports, Volume 9, Issue 5, September 2026.
ABSTRACT Introduction Urethral metastasis of prostate cancer is exceptionally rare, particularly in castration‐resistant disease. Therapy‐induced neuroendocrine prostate cancer (t‐NEPC) is an aggressive variant with limited treatment options. Case Presentation A 72‐year‐old man, 14 years after diagnosis of prostate adenocarcinoma treated with androgen ...
Toshiaki Kayaba, Satoshi Washino, Takanori Hayase, Kai Yazaki, Kimitoshi Saito, Tomoaki Miyagawa   +5 more
wiley   +1 more source

Dual‐Drug‐Loaded Liposomes: Design Strategies, Mechanistic Insights, and Therapeutic Applications in Cancer

MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
Dual‐drug‐loaded liposomes enable the simultaneous delivery of hydrophilic and hydrophobic therapeutics to tumors, enhancing anticancer efficacy and overcoming multidrug resistance. Through rational formulation design and surface functionalization, these systems improve tumor targeting, modulate efflux mechanisms and EMT, and achieve synergistic ...
Neelam Sinha, Rohan Chand Sahu, Rohit Patil, Dinesh Kumar, Ashish Kumar Agrawal   +4 more
wiley   +1 more source

Preimplantation genetic testing for concurrent Meckel Syndrome and hereditary breast cancer in a Chinese family harboring a novel NPHP3 pathogenic variant and a canonical BRCA2 frameshift variant. [PDF]

Genet Mol Biol
Zhang Y, Huang X, Qiu P, Ji H, Ding L, He X, Shi Y, Huang Y, Li P, Mei L.   +9 more
europepmc   +1 more source

Cyclins and Cyclin‐Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer

MedComm, Volume 7, Issue 9, September 2026.
This work synthesizes recent insights into the pathological roles of cyclins and cyclin‐dependent kinases (CDKs) across human cancers, highlights state‐of‐the‐art innovative approaches (especially targeted degradation and redistribution of CDK/cyclin proteins) for cancer therapy, and outlines future directions for CDK/cyclin‐related biomedical research.
Suya Zheng, Zhipeng Shen, Yuanfang Wu, Xingze Huang, Zhongyuan Zhang, Jiangyu Liu, Qichun Wei, Wenhao Chen, Ye Chen, Liang Xu   +9 more
wiley   +1 more source

The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial. [PDF]

Cancer Prev Res (Phila)
Senter L, Hovick S, Notestine R, Norden L, Benny N, Phillips S, Willoughby A, Pyatt R, Agnese D, Mak JS, DePersia A, Colonna SV, Maxwell WF, Kohlmann W, Spaeth EL, Gordon O, Thull D, Brock GN, Webb A, Smith RM, Toland AE.   +20 more
europepmc   +1 more source